Ladrx CORP

LADRX Corporation has initiated a General Assignment for the Benefit of Creditors, leading to a liquidation event and the cessation of substantially all business operations.

LadRx Corporation announced it will not pursue marketing approval for its drug aldoxorubicin under section 505(b)(2) due to insufficient resources, despite believing approval is possible.

Joel Caldwell resigned from LadRx Corporation's board of directors and all related committees, effective April 15, 2025.

LadRx Corporation held its 2024 Annual Meeting of Stockholders on October 4, 2024, where a director was elected and other proposals were approved.

LadRx Corporation has regained control of its aldoxorubicin drug after mutually terminating its license agreement with NantCell, and has amended its royalty agreement with XOMA.

LadRx Corporation reports a net loss for Q1 2025 while advancing its strategy for aldoxorubicin approval and LADR technology development.

LadRx Corporation reported a net loss of $1.9 million for the nine months ended September 30, 2024, and faces substantial doubt about its ability to continue as a going concern despite an expected milestone payment.

LadRx Corporation reported a net loss for the second quarter of 2024, while advancing its LADR7 drug candidate towards clinical trials.

LadRx Corporation reported a net income of $0.2 million for the first quarter of 2024, driven by a milestone payment, while also progressing its LADR technology platform.

LadRx Corporation announces its 2024 annual results, highlighting a net loss but outlining plans to pursue FDA approval for aldoxorubicin and advance its LADR-7 drug candidate.

LadRx Corporation's 2023 annual report highlights a shift towards advancing its LADR7 drug candidate after a strategic royalty agreement, despite ongoing operational losses.

LadRx Corporation has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.

LadRx Corporation will hold its 2024 Annual Meeting of Stockholders on October 4, 2024, to vote on the election of a director, ratification of the independent accounting firm, and an advisory vote on executive compensation.